Additional information
| Description | Glyco-obeticholic acid, an active metabolite of obeticholic acid (6-ECDCA; Item No. 11031), acts as an agonist of the farnesoid X receptor (FXR) and is a semisynthetic derivative of chenodeoxycholic acid (Item No. 10011286) [1]. It is produced through glycine conjugation in the liver from obeticholic acid and can revert back to its precursor through microbial deconjugation in the ileum and colon [1]. Glyco-obeticholic acid has been utilized in developing bile acid analogs that function as agonists for both FXR and TGR5 receptors [2]. |
|---|---|
| References | 1. Markham, A., and Keam, S.J. Obeticholic acid: First global approval. Drugs 76(12), 1221-1226 (2016). |
